[1] Eisinger RW, Fauci AS. Ending the global HIV epidemic begins at the individual national level: an update from the United States. China CDC Wkly, 2020; 2, 764−6. doi:  10.46234/ccdcw2020.163
[2] Bershteyn A, Jamieson L, Kim HY, et al. Transmission reduction, health benefits, and upper-bound costs of interventions to improve retention on antiretroviral therapy: a combined analysis of three mathematical models. Lancet Glob Health, 2022; 10, e1298−306. doi:  10.1016/S2214-109X(22)00310-2
[3] Hayes RJ, Donnell D, Floyd S, et al. Effect of universal testing and treatment on HIV incidence - HPTN 071 (PopART). N Engl J Med, 2019; 381, 207−18. doi:  10.1056/NEJMoa1814556
[4] Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med, 2016; 375, 830−9. doi:  10.1056/NEJMoa1600693
[5] Heath K, Levi J, Hill A. The joint United Nations Programme on HIV/AIDS 95-95-95 targets: worldwide clinical and cost benefits of generic manufacture. AIDS, 2021; 35, S197−203. doi:  10.1097/QAD.0000000000002983
[6] Han MJ. Analysis of the HIV epidemic situation in China and prospects for prevention and treatment. Chin J AIDS STD, 2023; 29, 247−50. (In Chinese)
[7] Zhao Y, Gan XM, Zhao DC, et al. The progress of HIV antiretroviral therapy in China and the consideration of promoting high-quality development. Chin J AIDS STD, 2023; 29, 619−22. (In Chinese)
[8] Zhao Y, Han MJ, Gan XM, et al. Characteristics and viral suppression among people living with HIV from the national free antiretroviral therapy programme, 2019. HIV Med, 2020; 21, 701−7. doi:  10.1111/hiv.13020
[9] Zhang FJ, Ma Y. Progress and challenges in China’s free ART programme. Lancet HIV, 2019; 6, e8−9. doi:  10.1016/S2352-3018(18)30364-3
[10] Xu P, Han MJ, Lyu F, et al. Evidence-based basis and practice strategy for the high-quality development of AIDS prevention and treatment in China. Chin J AIDS STD, 2023; 29, 491−3. (In Chinese)
[11] Liu F. Overview and prospect of reform of China’s medical insurance and policy evolution. Chin Banker, 2022; 118-23. (In Chinese)
[12] Pan F, Zhao H. HIV prevention and treatment has entered a new era of whole-course management: interview with Professor Li Taisheng, director of the Department of Infection Medicine of Peking Union Medical College Hospital. China Med Pharm, 2022; 12, 1−5. (In Chinese)
[13] National Healthcare Security Administration, Ministry of Human Resources and Social Security. National Healthcare Security Administration, Ministry of Human Resources and Social Security, Notice on the issuance of the catalogue of drugs for national basic medical insurance, work-related injury insurance and maternity insurance (2022). http://www.nhsa.gov.cn/art/2023/1/18/art_104_10078.html. [2023-01-18]. (In Chinese)
[14] Lockman S, Brummel SS, Ziemba L, et al. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet, 2021; 397, 1276−92. doi:  10.1016/S0140-6736(21)00314-7
[15] Chinula L, Ziemba L, Brummel S, et al. Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet HIV, 2023; 10, e363−74. doi:  10.1016/S2352-3018(23)00061-9
[16] Peng XY. Feasibility study on the inclusion of HIV/AIDS antiviral therapy in medical insurance. Chinese Center for Disease Control and Prevention. 2018. (In Chinese)
[17] Xiong JJ, Yang G, Huang LH, et al. Problems and history of the policies on medical insurance for people living with HIV/AIDS in China. Med Soc, 2015; 28, 2−5. (In Chinese)
[18] Hu JK, Zhang G, Xu P, et al. The situation of HIV/AIDS patients using outpatient policy for special diseases for ART in some cities. Chin J AIDS STD, 2023; 29, 534−8. (In Chinese)
[19] General Office of the State Council of the People’s Republic of China. Notice of the General Office of the State Council on the issuance of the reform plan for the division of financial powers and expenditure responsibilities between central and local governments in the field of medical and health care. http://www.gov.cn/zhengce/content/2018-08/13/content_5313489.htm. [2018-08-13]. (In Chinese)
[20] He QS, Hao C, Pan D, et al. Adherence to antiretroviral therapy and its predictive factors among people living with HIV in China: a behavioral theory-based prospective cohort study. Int J Behav Med, 2023; 30, 555−65. doi:  10.1007/s12529-022-10120-7
[21] Xie JZ, Gu JY, Chen XY, et al. Baseline and process factors of anti-retroviral therapy that predict loss to follow-up among people living with HIV/AIDS in China: a retrospective cohort study. AIDS Behav, 2022; 26, 1126−37. doi:  10.1007/s10461-021-03466-8
[22] Zhang T, Ding HB, An MH, et al. Factors associated with high-risk low-level viremia leading to virologic failure: 16-year retrospective study of a Chinese antiretroviral therapy cohort. BMC Infect Dis, 2020; 20, 147. doi:  10.1186/s12879-020-4837-y
[23] The Chinese Center for Disease Control and Prevention Sexually Transmitted Disease of AIDS Prevention and Control Center. China free antiretroviral treatment manual. 5th ed. People’s Medical Publishing House. 2023. (In Chinese)
[24] Hu JK, Xu P, Xu J, et al. Medical security policy on AIDS ART and its implementation status in China. Chin J AIDS STD, 2023; 29, 1156−9. (In Chinese)
[25] He N. Research progress in the epidemiology of HIV/AIDS in China. China CDC Wkly, 2021; 3, 1022−30. doi:  10.46234/ccdcw2021.249
[26] Zhao C, Xiang XC, Guo KW, et al. Study on knowledge, attitudes and behaviours about AIDS among undergraduates of China. Curr HIV Res, 2021; 19, 304−10. doi:  10.2174/1570162X18666201218121200
[27] Belay YA, Yitayal M, Atnafu A, et al. Patients’ preferences for antiretroviral therapy service provision: a systematic review. Cost Eff Resour Alloc, 2021; 19, 56. doi:  10.1186/s12962-021-00310-7
[28] Wang YD. Analysis of influencing factors of new generation off-farm workers participating in social medical insurance. Econ Res Guide, 2023; 86-8. (In Chinese)
[29] Wei Y. Research on the definition and classification of medical assistance objects. Chin Primary Health Care, 2022; 36, 15−8. (In Chinese)
[30] Ji DJ. The economic burden analysis of people living with HIV/AIDS from the men who have sex with men. Southeast University. 2016. (In Chinese)
[31] Osiyemi O, De Wit S, Ajana F, et al. Efficacy and safety of switching to dolutegravir/lamivudine versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: results through week 144 from the phase 3, noninferiority TANGO randomized trial. Clin Infect Dis, 2022; 75, 975−86. doi:  10.1093/cid/ciac036
[32] Santevecchi BA, Miller S, Childs-Kean LM. Doing more with less: review of dolutegravir-lamivudine, a novel single-tablet regimen for antiretroviral-naïve adults with HIV-1 infection. Ann Pharmacother, 2020; 54, 1252−9. doi:  10.1177/1060028020933772
[33] Nyblade L, Mingkwan P, Stockton MA. Stigma reduction: an essential ingredient to ending AIDS by 2030. Lancet HIV, 2021; 8, e106−13. doi:  10.1016/S2352-3018(20)30309-X